MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
9.47
+0.50 (5.57%)
Apr 13, 2026, 2:43 PM EDT - Market open
MeiraGTx Holdings Revenue
In the year 2025, MeiraGTx Holdings had annual revenue of $81.39M with 144.57% growth. MeiraGTx Holdings had revenue of $75.36M in the quarter ending December 31, 2025, with 252.33% growth.
Revenue (ttm)
$81.39M
Revenue Growth
+144.57%
P/S Ratio
9.47
Revenue / Employee
$201,963
Employees
403
Market Cap
771.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 81.39M | 48.11M | 144.57% |
| Dec 31, 2024 | 33.28M | 19.26M | 137.42% |
| Dec 31, 2023 | 14.02M | -1.90M | -11.95% |
| Dec 31, 2022 | 15.92M | -21.78M | -57.77% |
| Dec 31, 2021 | 37.70M | 22.14M | 142.25% |
| Dec 31, 2020 | 15.56M | 2.27M | 17.09% |
| Dec 31, 2019 | 13.29M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 262.60M |
| Maravai LifeSciences Holdings | 185.74M |
| Gyre Therapeutics | 116.59M |
| Kura Oncology | 67.48M |
| Lexicon Pharmaceuticals | 49.80M |
MGTX News
- 18 days ago - MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results - GlobeNewsWire
- 2 months ago - ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy - PRNewsWire
- 5 months ago - Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference - PRNewsWire
- 5 months ago - MeiraGTx Reports Third Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 5 months ago - Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease - Reuters
- 5 months ago - MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology - GlobeNewsWire
- 6 months ago - MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - GlobeNewsWire
- 8 months ago - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results - GlobeNewsWire